|
|
View Clinical Trial (Medical Research Study)
|
Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers - NCT00984919-48201 (Clinical Trial 403453)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy403453.aspx
|
** Please review additional "Nearby Studies" on right ----->
|
|
 |
 |
|
| City: |
|
Detroit |
|
State:
|
|
MI |
| Zip Code: |
|
48201 |
| Conditions: |
|
Prostate Cancer |
| Purpose: |
|
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory
may help doctors identify biomarkers related to cancer.
PURPOSE: This research study is looking at a biomarker, 11-dh-TXB2, in blood and urine
samples from patients with prostate cancer and healthy volunteers.
|
| Study summary: |
|
OBJECTIVES:
- To identify a potential novel marker of prostate cancer in the blood and urine,
11-dh-TXB2, to be used as a screening tool for prostate cancer as well as in detection
of early relapse in patients previously treated for early-stage prostate cancer.
OUTLINE: Blood and urine samples are collected and analyzed for plasma and urinary
11-dh-TXB2 levels by HPLC and tandem-mass spectrometry. |
| Criteria: |
|
DISEASE CHARACTERISTICS:
- Meets one of the following criteria:
- Histopathologically confirmed prostate cancer meeting 1 of the following
criteria:
- Newly diagnosed untreated disease
- Received prior local therapy (prostatectomy, definitive radiotherapy,
brachytherapy, or cryotherapy) with no evidence of disease activity
(defined as serum PSA < 0.4 ng/mL post therapy) and by imaging studies
- Experienced biochemical failure (defined as rise in serum PSA ≥ 0.4 ng/mL
post therapy)
- Healthy volunteer (clinic patient with no history of clinically significant
malignancies within the past 6 months)
PATIENT CHARACTERISTICS:
- No clinical evidence of liver cirrhosis or chronic liver disease (i.e., evidence of
ascites or severe coagulopathy)
- No active prostatitis
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 30 days since prior and no concurrent regular antiplatelet agents
(including aspirin, anagrelide, cilastazole, clopidogrel, dipyridamole,
pentoxiphylline, sulfinpyrazone, or ticlopidine)
- More than 7 days since prior and no concurrent NSAIDs (including ibuprofen,
celecoxib, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, indomethacin,
ketoprofen, meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin,
piroxicam, sulindac, or tolmetin) |
|
|
|
| Study is available at: |
|
Barbara Ann Karmanos Cancer Institute
Detroit, MI 48201
United States
Primary Contact:
Clinical Trials Office - Barbara Ann Karmanos Cancer Institute
Phone: 313-576-9363 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 16, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|
|
|
|